OR WAIT null SECS
Check out the latest features and columns!
Pharm Exec profiles its 2022 Emerging Pharma Leaders
Biopharma experts at the forefront of applying real-world data and real-world evidence across the product life cycle converge to discuss the lingering challenges in fully realizing the vast potential of these insights to transform the value equation
June's Executive Profile features Tremeau CEO, Bradford Sippy
The windfall from COVID-19 vaccines and treatments has shaken up Pharm Exec’s latest listing of the top global biopharma sales producers in record-breaking fashion
Highlighted Videos
June 28, 2022
Board Certified Biologics and Biosimilars Specialist (BCBBS) program will launch in 2022.
June 27, 2022
Amid push to include this population more in clinical trials, the goal is to uncover improved evidence on the risks/benefits of drugs for these patients.
June 24, 2022
Takes aim at actions that limit access to lower-cost drugs, calls for revamp of M&A-impact guidelines.
June 23, 2022
In episode 111, Kevin Ali, CEO of Organon, talks about how’s he’s lead the launch of a new niche company for women’s health, and what he hopes it can achieve.
June 22, 2022
Mr. Horvath, who brings over a decade of experience in pharmaceutical commercialization, will lead the commercialization of POINT’s pipeline.
Agency leaders seek to build public trust in science and gain support for regulation.
June 20, 2022
Matterkind uses DeepIntent Outcomes’ patented technology to improve audience quality and script performance.
Additions of Andrew Johnson and Bridget Seay strengthen epocrates’ evolution as a commercial organization with best-in-class market intelligence and products.
The world’s largest cancer research meeting, the American Society of Clinical Oncology (ASCO) Annual Meeting, recently convened in person in Chicago after two years of being held virtually. Sara Baker and Kristine Austria Fan of Marina Maher Communications provide their takeaways from the meeting.
June 17, 2022
We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.
